Myostatin - Clinical Research

Clinical Research

Further research into myostatin and the myostatin gene may lead to therapies for muscular dystrophy. The idea is to introduce substances that block myostatin. A monoclonal antibody specific to myostatin increases muscle mass in mice. Similar results in monkeys were obtained.

A two-week treatment of normal mice with soluble activin type IIB receptor, a molecule that is normally attached to cells and binds to myostatin, leads to a significantly increased muscle mass (up to 60%). It is thought that binding of myostatin to the soluble activin receptor prevents it from interacting with the cell-bound receptors.

It remains unclear as to whether long-term treatment of muscular dystrophy with myostatin inhibitors is beneficial, as the depletion of muscle stem cells could worsen the disease later on. As of 2012, no myostatin-inhibiting drugs for humans are on the market, but an antibody genetically engineered to neutralize myostatin was developed by New Jersey pharmaceutical company Wyeth. The inhibitor is called MYO-029, but, after an initial clinical trial, Wyeth says they will not be developing the drug. Some athletes, eager to get their hands on such drugs, turn to the internet, where fake "myostatin blockers" are being sold.

Myostatin levels are effectively decreased by creatine supplementation.

A technique for detecting mutations in myostatin variants has been developed.

Read more about this topic:  Myostatin

Famous quotes containing the word research:

    The great question that has never been answered and which I have not get been able to answer, despite my thirty years of research into the feminine soul, is “What does a women want?”
    Sigmund Freud (1856–1939)